News

New CDC data show fewer kindergartners are fully vaccinated as exemption rates increased during the 2024-2025 school year.

A look back at the FDA submissions and regulatory decisions in the pediatric health care space from July 2025.

Take a quick look at everything you may have missed last month, including the top FDA approvals and latest clinical updates.

The FDA approved concizumab-mtci (Alhemo; Novo Nordisk) for hemophilia A/B without inhibitors, offering once-daily subcutaneous prophylaxis that significantly reduces bleeding rates.

Elizabeth Reichert, PhD, shares practical tips for pediatricians to help families monitor teen media use and recognize early signs of anxiety.

Pediatricians are urged to follow 2024 guidelines amid ACIP upheaval, vaccine hesitancy, and access issues as children head back to school.

Richard Auchus, MD, PhD, highlights data showing that crinecerfont use in children with CAH can improve metabolic outcomes.

“While our study is small, its results are powerful and have implications not only for MIS-C, but potentially for long COVID,” said lead author Lael Yonker, MD.

Many families face common potty training challenges, including anxiety and setbacks, highlighting the need for patience and personalized strategies.

Nektar Therapeutics remains on track to announce top-line phase 2 data in December.

Pegcetacoplan (Empaveli; Apellis Pharmaceuticals) is indicated for patients 12 years or older to reduce proteinuria.

Suzanne Hollander, MS, RD, LDN; and Timothy Tramontana, MD, offer thoughts on newly FDA-approved sepiapterin for PKU.

“Without treatment, individuals with PKU would have very high blood Phe levels...so that results in neurocognitive deficits and mood disorders," Suzanne Hollander, MS, RD, LDN, said.

The FDA has approved avatrombopag and new sprinkle formulation for children ≥1 year with chronic ITP, offering an oral, food-flexible treatment option.

The study enrolled infants not selected for risk, a population that has been seldom studied with regard to emollient intervention.

Of the 253 influenza-related pediatric deaths through June 21, 2025, 42.7% occurred in children without a high-risk medical condition.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Study links early childhood eczema timing to risk of allergies like food allergy, asthma, and rhinitis, with five distinct disease phenotypes identified.

Lori Handy, MD, MSCE, highlights how pediatricians can better prepare families and systems for missed vaccines during the back-to-school rush.

Tyra Bryant-Stephens, MD, encourages families to revisit asthma triggers, refill medications, and manage allergies to prevent avoidable complications.

Most youth with type 1 diabetes in sub-Saharan Africa lack autoimmune markers, suggesting a distinct, non-autoimmune form of insulin-deficient diabetes.

This week, HHS Secretary Robert F. Kennedy Jr signed the ACIP's recommendation to remove the mercury-based preservative from all influenza vaccines.

Can you guess the diagnosis?

Solid Biosciences is planning a phase 1b clinical trial of SGT-501 to treat the catecholaminergic polymorphic ventricular tachycardia heart condition.

Nirsevimab reduced RSV-related illness by up to 98% and lowered the amount of hospitalizations and health care use among healthy term infants in a real-world study.

Can you diagnose this patient? Take our poll and find out! Then check back for the full case, differential diagnosis, and correct diagnosis.

John Browning, MD, highlights the importance of fragrance-free, steroid-free creams in managing atopic dermatitis safely and effectively in children.

A new polygenic risk score enhances obesity risk prediction from childhood to adulthood, offering new insights for early intervention and prevention strategies.